Moffitt Cancer Center | Strategic Alliance Partners

Julio C. Chavez, MD, MS, discusses updated data from the European Hematology Association (EHA) 2025 Congress on the investigational oral CELMoD agent golcadomide (GOLCA) plus rituximab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses what oncology pharmacists should understand about rucaparib when treating ovarian cancer.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses how dosing for rucaparib treatment is assessed to treat patients with ovarian cancer.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses the efficacy of rucaparib for approved indications based on clinical trial results.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses how rucaparib is currently used when treating patients with ovarian cancer.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses the mechanism of action of rucaparib in recurrent and second line ovarian cancer, fallopian tube cancer, and peritoneal cancer.

Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses the overall impact of the research assessing lutetium Lu 177 dotatate for midgut neuroendocrine tumors.

Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses patients reports of their quality of life while being treated with lutetium Lu 177 dotatate for midgut neuroendocrine tumors.

Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses some of the adverse events patients experienced during the phase 3 trial assessing lutetium Lu 177 dotatate for midgut neuroendocrine tumors.

Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses the methods used during the phase 3 trial to assess lutetium Lu 177 dotatate for midgut neuroendocrine tumors.

Kenneth Komorny, PharmD, BCPS, a co-lead on development of National Comprehensive Cancer Network recommendations for biosimilar management, explains some of the positions the NCCN has taken.

These nationally recognized health system and oncology leaders will join the esteemed SAP Program.

Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute speaks about why data are limited in myelofibrosis.

Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute speaks about factors in treatment decisions for patients with myelofibrosis.

Melissa B. Armitage, PharmD, BCOP, a clinical pharmacist who works in breast oncology at the Moffitt Cancer Center in Tampa, Florida, discussed this disease's pathophysiology, natural progression, and risk factors.